Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia
Kura Oncology’s ziftomenib addresses a specific genetic mutation present in about 30% of cases of acute myeloid leukemia. Data from the drug’s pivotal Phase 2 test were presented during the annual meeting of the American Society of Clinical Oncology. The post Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia appeared first on MedCity News.
Kura Oncology’s ziftomenib addresses a specific genetic mutation present in about 30% of cases of acute myeloid leukemia. Data from the drug’s pivotal Phase 2 test were presented during the annual meeting of the American Society of Clinical Oncology.
The post Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia appeared first on MedCity News.
